Adaptimmune has initiated a phase I/II safety and tolerability study of its affinity enhanced T-cell therapy targeting the NY-ESO-1 cancer antigen in patients with non-small cell lung cancer (NSCLC).
Adaptimmune is developing the affinity enhanced T-cell therapy targeting the NY-ESO-1 antigen under a collaboration agreement with GlaxoSmithKline (GSK). Located in Oxford (UK) this clinical stage biotech is investigating around 30 intracellular target peptides (preferentially expressed in cancer cells), of which 12 are currently being progressed through unpartnered research programs.
Their NY-ESO TCR therapeutic candidate will be trialed in an open label clinical study for up to 10 patients with locally advanced or metastatic Stage IIIb or Stage IV NSCLC. To be eligible, the patient has to be of a certain allelic type to express the NY-ESO-1 tumor antigen, which will be targeted by the autologous T-cell therapy.
However, not all is bright and clear for Adaptimmune’s future, despite a massive IPO of €156.7M in May.